NCT00474383View on ClinicalTrials.gov

An Safety and Efficacy Study of Abiraterone Acetate in Participants With Advanced Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy

PHASE2CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

August 31, 2011

Study Completion Date

August 31, 2011

Conditions
Prostate Neoplasms
Interventions
DRUG

Abiraterone acetate

Abiraterone acetate 1000 milligram (mg) capsule or tablet will be administered orally, once daily continuously in 28-day cycle up to disease progression, death, or end of study.

DRUG

Glucocorticoid

Prednisone/prednisolone 5 mg tablet orally twice daily/dexamethasone 0.5 mg tablet orally once daily continuously in 28-day cycle up to disease progression, death, or end of study.

Trial Locations (3)

Unknown

San Francisco

New York

Sutton

Sponsors
All Listed Sponsors
lead

Cougar Biotechnology, Inc.

INDUSTRY